Showing results (131-140 of 163) with videos related to

Sort By:
Pageof 17
Annals of the Rheumatic Diseases|January 24, 2018
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practiceChristian Dejaco, Sofia Ramiro, Christina Duftner, et al.
Annals of the Rheumatic Diseases|February 6, 2025
GM-CSF drives IL-6 production by macrophages in polymyalgia rheumaticaWilliam F Jiemy, Anqi Zhang, Wayel H Abdulahad, et al.
The New England Journal of Medicine|June 3, 2026
Phase 3 Trial of Secukinumab in Polymyalgia RheumaticaJohn H Stone, Frank Buttgereit, Alain Saraux, et al.
Annals of the Rheumatic Diseases|July 5, 2019
2018 Update of the EULAR recommendations for the management of large vessel vasculitisBernhard Hellmich, Ana Agueda, Sara Monti, et al.
Annals of the Rheumatic Diseases|March 3, 2016
Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task forceCindy Strehl, Johannes W J Bijlsma, Maarten de Wit, et al.
Annals of the Rheumatic Diseases|May 8, 2012
Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndromeJulia L Newton, James Frith, Danielle Powell, et al.
Annals of the Rheumatic Diseases|June 14, 2013
Health-related utility values of patients with primary Sjögren's syndrome and its predictorsDennis Lendrem, Sheryl Mitchell, Peter McMeekin, et al.
Annals of the Rheumatic Diseases|August 7, 2023
EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice: 2023 updateChristian Dejaco, Sofia Ramiro, Milena Bond, et al.
Swiss Medical Weekly|February 15, 2018
Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome RegistryAlexandre Dumusc, Wan-Fai Ng, Katherine James, et al.
Lancet (London, England)|January 24, 2021
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trialFrances Humby, Patrick Durez, Maya H Buch, et al.
Pageof 17